Venture Capital News Daily
   Your Source for Venture Capital and Private Equity Financings
   Massinvestor/VC News Daily      
   Venture Capital News Daily on RSS Venture Capital News Daily on Facebook Venture Capital News Daily on Twitter
VC DATABASE   /   MOBILE APP  /  CELEBRITY VCs   /   VENTURE TRACKR   /   ARCHIVE   /   ABOUT US
VC-funded Company:


Nkarta Therapeutics
6000 Shoreline Court, Suite 102
South San Francisco, CA 94080
https://www.nkartatx.com/

Nkarta Therapeutics was founded on the proprietary, robust and well characterized Natural Killer (NK) cell expansion technology pioneered by Dr. Dario Campana. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. Nkarta is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. Nkarta's goal is to develop off-the-shelf NK cell therapy product candidates to improve outcomes for patients.

Key Contact
NameTitleE-Mail
Paul HastingsCEO


Funding Events
DateAmountTypeInvestors
09/05/19$114,000,000Series B Amgen Ventures
Deerfield Management Company, L.P.
Life Sciences Partners
Logos Capital
NEA Ventures
Novo Holdings
RA Capital
Samsara BioCapital  
SR One
 
Massinvestor/VC News Daily
617-620-4606


© 2018 Massinvestor, Inc.